v3.23.3
Segment Information
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segment Information Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.The following table details AbbVie’s worldwide net revenues:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)
2023202220232022
Immunology
HumiraUnited States$3,020 $4,956 $9,420 $13,613 
International527 603 1,680 2,045 
Total$3,547 $5,559 $11,100 $15,658 
SkyriziUnited States$1,875 $1,221 $4,648 $3,081 
International251 176 721 508 
Total$2,126 $1,397 $5,369 $3,589 
RinvoqUnited States$801 $505 $1,895 $1,228 
International309 190 819 524 
Total$1,110 $695 $2,714 $1,752 
Oncology
ImbruvicaUnited States$678 $849 $1,982 $2,585 
Collaboration revenues230 286 711 868 
Total$908 $1,135 $2,693 $3,453 
VenclextaUnited States$281 $259 $811 $740 
International309 256 888 753 
Total$590 $515 $1,699 $1,493 
EpkinlyCollaboration revenues$14 $— $14 $— 
Aesthetics
Botox CosmeticUnited States$388 $370 $1,217 $1,232 
International232 267 747 741 
Total$620 $637 $1,964 $1,973 
Juvederm CollectionUnited States$116 $125 $363 $420 
International205 227 681 686 
Total$321 $352 $1,044 $1,106 
Other AestheticsUnited States$255 $265 $785 $837 
International43 47 130 130 
Total$298 $312 $915 $967 
Neuroscience
Botox TherapeuticUnited States$626 $584 $1,827 $1,641 
International122 115 388 350 
Total$748 $699 $2,215 $1,991 
Vraylar
United States$750 $554 $1,967 $1,473 
International1 — 3 — 
Total$751 $554 $1,970 $1,473 
DuodopaUnited States$25 $22 $74 $72 
International93 88 279 279 
Total$118 $110 $353 $351 
UbrelvyUnited States$230 $160 $574 $483 
International3 — 7 — 
Total$233 $160 $581 $483 
Three months ended
September 30,		Nine months ended
September 30,
(in millions)
2023202220232022
QuliptaUnited States$131 $62 $292 $106 
International1 — 2 — 
Total$132 $62 $294 $106 
Other NeuroscienceUnited States$55 $82 $195 $400 
International6 5 15 14 
Total$61 $87 $210 $414 
Eye Care
OzurdexUnited States$34 $35 $107 $104 
International86 71 247 219 
Total$120 $106 $354 $323 
Lumigan/GanfortUnited States$28 $59 $142 $186 
International63 62 198 205 
Total$91 $121 $340 $391 
Alphagan/CombiganUnited States$30 $37 $90 $161 
International40 36 116 111 
Total$70 $73 $206 $272 
RestasisUnited States$104 $132 $265 $518 
International13 10 43 38 
Total$117 $142 $308 $556 
Other Eye CareUnited States$114 $99 $334 $296 
International93 82 288 273 
Total$207 $181 $622 $569 
Other Key Products
MavyretUnited States$167 $190 $531 $562 
International203 193 590 599 
Total$370 $383 $1,121 $1,161 
CreonUnited States$305 $336 $892 $941 
Linzess/ConstellaUnited States$279 $262 $799 $742 
International9 9 26 24 
Total$288 $271 $825 $766 
All other$782 $925 $2,214 $3,145 
Total net revenues$13,927 $14,812 $40,017 $42,933